A pivotal animal model for development of anticancer molecules is mice with subcutaneous tumors, grown by injection of xenografted tumor cells, where micro-Computed Tomography (µCT) of the mice is used to analyze the efficacy of the anticancer molecule. Manual delineation of the tumor region is necessary for the analysis, which is time-consuming and inconsistent, highlighting the need for automatic segmentation (AS) tools. This study introduces a preclinical µCT database, comprising 452 whole-body scans from 223 individual mice with subcutaneous tumors, spanning ten diverse µCT datasets conducted between 2014 and 2020 on a preclinical PET/CT scanner, making it the hitherto largest dataset of its kind. Each tumor is annotated manually by three expert annotators, allowing for robust model development. Inter-annotator agreement was analyzed, and we report an overall annotation agreement of 0.903 ± 0.046 (mean ± std) Fleiss' Kappa and a mean deviation in volume estimation of 0.015 ± 0.010 cm3 (6.9% ± 4.7), which establishes a human baseline accuracy for delineation of subcutaneous tumors, while showing good inter-annotator agreement.
The use of fibroblast activation protein inhibitors (FAPis) for positron emission tomography (PET) imaging in cancer has garnered significant interest in recent years, yielding promising results in preclinical and clinical settings. FAP is predominantly expressed in pathological conditions such as fibrosis and cancer, making it a compelling target. An optimized approach involves using FAPi homodimers as PET tracers, which enhance tumor uptake and retention, making them more effective candidates for therapy. Here, a UAMC-1110 inhibitor-based homodimer, DOTAGA-Glu(FAPi)2, was synthesized and radiolabeled with gallium-68, and its efficacy was evaluated in vivo for PET imaging in an endogenously FAP-expressing xenografted mouse model, U87MG. Notably, 45 min post-injection, the mean uptake of [68Ga]Ga-DOTAGA-Glu(FAPi)2 was 4.7 ± 0.5% ID/g in the tumor with low off-target accumulation. The ex vivo analysis of the FAP expression in the tumors confirmed the in vivo results. These findings highlight and confirm the tracer’s potential for diagnostic imaging of cancer and as a theranostic companion.
Preclinical computed tomography (CT) is extensively used for anatomical reference and multimodal imaging, but the soft tissue contrast is poor compared to clinical CT. This hinders reliable organ delineation and segmentation in small-animal studies. We present a systematic evaluation of commonly used clinical iodinated and gadolinium-based contrast agents, together with a preclinical nanoparticle-based contrast agent. This evaluation aims to enhance soft-tissue boundary definition and in vivo visibility. The study consisted of two parts. First, phantom experiments were performed to assess the relationship between contrast-agent concentration and Hounsfield Unit (HU) across multiple dilutions and CT energy settings. Second, these findings were evaluated in vivo in mice to assess organ-level enhancement. Phantom measurements demonstrated a linear relationship between HU and concentration for all agents; however, at higher dilutions, contrast enhancement became indistinguishable from the background. In vivo, clinical iodinated and gadolinium-based agents administered intraperitoneal (IP) provided enhanced soft-tissue contrast by outlining abdominal organs, whereas the intravenously administered nanoparticle agent exhibited pronounced organ-specific accumulation. Overall, IP injection of clinical iodinated contrast agents offers a cost-effective and practical strategy for enhancing organ boundary visibility in preclinical CT. For longitudinal or organ-specific imaging studies, the preclinical nanoparticle-based contrast agent remains advantageous, as its cumulative uptake allows detection over extended periods and minimizes burden from multiple injections.